Celon Pharma S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
For the nine months, revenue was PLN 139.8 million compared to PLN 146.19 million a year ago. Net loss was PLN 27.29 million compared to PLN 7.53 million a year ago. Basic loss per share from continuing operations was PLN 0.53 compared to PLN 0.15 a year ago. Diluted loss per share from continuing operations was PLN 0.53 compared to PLN 0.15 a year ago.